drugset / Trial / NCT02283827

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

NCT02283827

Phase 1 Completed 32 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Single centre, open-label, multiple doses, two parallel study groups each receiving two formulations in a one-sequence design

Timeline

Start
2007-01
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg
Subject Phenytoin Unknown 300 mg

Indications